Breaking Finance News

Zacks Investment Research downgraded Concert Pharmaceuticals Inc (NASDAQ:CNCE) to Sell in a report released today.

Zacks Investment Research has downgraded Concert Pharmaceuticals Inc (NASDAQ:CNCE) to Sell in a report released on 10/11/2016.

Previously on 6/24/2015, Ladenburg Thalmann reported on Concert Pharmaceuticals Inc (NASDAQ:CNCE) raised the target price from $24.00 to $27.00. At the time, this indicated a possible upside of 0.63%.

Yesterday Concert Pharmaceuticals Inc (NASDAQ:CNCE) traded -3.78% lower at $9.76. The company’s 50-day moving average is $9.97 and its 200-day moving average is $11.72. The last closing price is down -24.03% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 103,315 shares of the stock were exchanged, down from an average trading volume of 107,337

See Chart Below

Concert Pharmaceuticals Inc (NASDAQ:CNCE)

Concert Pharmaceuticals Inc has a 52 week low of $8.83 and a 52 week high of $25.04 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 6 brokers have issued a report on the stock. The consensus target price is $28.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Concert Pharmaceuticals Inc (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company's deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company's product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *